← Leaderboards
Michelle A Petri
Johns Hopkins University
$20,289,441
Attributed
$24,150,629
Total exposure
33
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,150,629 · 33
By mechanism
R01$14,163,997 · 4
UC2$5,148,251 · 1
UH2$2,078,368 · 1
M01$1,669,825 · 24
U01$499,501 · 1
P50$407,117 · 1
Top collaborators
- Jill P Buyon6 shared
- Brad H Rovin6 shared
- Victoria P Werth6 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Jennifer A Haythornthwaite$14,995,955
- Robert A Brodsky$10,132,414
- Lewis C Becker$35,680,196
- Livia A Casciola-Rosen$11,279,825
- Sandra E. Guggino$3,361,350
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusClinical ResearchHuman SubjectLupusAtherosclerosisOrganLeadKidneyCohortUrineCollaborationsProtocols DocumentationEpidemiologyMonitorSamplingSiteMedicinePathway InteractionsLaboratoriesHuman Therapy EvaluationLongitudinal Human StudyBiological MarkersResearch PersonnelPrograms
Grant awards (92)
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,249,871
UC2 · FY2025 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$600,000
UC2 · FY2024 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$288,149
UC2 · FY2024 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,600,000
UC2 · FY2023 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain Supplement$356,561
UC2 · FY2023 · AR
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT)$1,053,670
UC2 · FY2022 · AR
Hopkins Lupus Cohort$673,347
R01 · FY2020 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$109,611
UH2 · FY2020 · AR · contact PI
Hopkins Lupus Cohort$685,589
R01 · FY2019 · AR · contact PI
Hopkins Lupus Cohort$685,589
R01 · FY2018 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$268,909
UH2 · FY2018 · AR · contact PI
Hopkins Lupus Cohort$684,655
R01 · FY2017 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$510,599
UH2 · FY2017 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$127,238
UH2 · FY2017 · AR · contact PI
Hopkins Lupus Cohort$698,318
R01 · FY2016 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$379,486
UH2 · FY2016 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$163,000
UH2 · FY2016 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$119,523
UH2 · FY2016 · AR · contact PI
Hopkins Lupus Cohort$662,805
R01 · FY2015 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$200,001
UH2 · FY2015 · AR · contact PI
Hopkins Lupus Cohort$682,380
R01 · FY2014 · AR · contact PI
Accelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)$200,001
UH2 · FY2014 · AR · contact PI
Hopkins Lupus Cohort$608,985
R01 · FY2013 · AR · contact PI
Hopkins Lupus Cohort$641,036
R01 · FY2012 · AR · contact PI
Hopkins Lupus Cohort$638,643
R01 · FY2010 · AR · contact PI
Hopkins Lupus Cohort$643,595
R01 · FY2009 · AR · contact PI
Hopkins Lupus Cohort$662,654
R01 · FY2008 · AR · contact PI
Revision of ACR Classification Criteria for Systemic Lupus Erythematosus$246,076
U01 · FY2007 · AR · contact PI
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY AND PREDICTORS OF MORBIDITY$94,286
M01 · FY2007 · RR · contact PI
BRAIN CONNECTIONS: ADD-ON STUDY OF SERIAL BRAIN MRIS EVERY SIX MONTHS$825
M01 · FY2007 · RR · contact PI
COGNITIVE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS$263
M01 · FY2007 · RR · contact PI
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)$188
M01 · FY2007 · RR · contact PI
LUPUS ATHEROSCLEROSIS PREVENTION STUDY (LAPS)$104
M01 · FY2007 · RR · contact PI
Lupus Cohort$601,564
R01 · FY2006 · AR · contact PI
Brain Connections$384,990
R01 · FY2006 · AR · contact PI
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY AND PREDICTORS OF MORBIDITY$337,678
M01 · FY2006 · RR · contact PI
LUPUS ATHEROSCLEROSIS PREVENTION STUDY (LAPS)\PAR }$43,379
M01 · FY2006 · RR · contact PI
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)$14,111
M01 · FY2006 · RR · contact PI
BRAIN CONECTIONS: ADD-ON STUDY OF SERIAL BRAIN MRIS EVERY SIX MONTHS$6,850
M01 · FY2006 · RR · contact PI
LUPUS ATHEROSCLEROSIS PREVENTION STUDY (LAPS) SUPPLEMENT$959
M01 · FY2006 · RR · contact PI
Lupus Cohort$616,409
R01 · FY2005 · AR
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY AND PREDICTORS OF MORBIDITY$592,886
M01 · FY2005 · RR
Brain Connections$419,257
R01 · FY2005 · AR
Revision of ACR Classification Criteria for SLE$253,425
U01 · FY2005 · AR
LUPUS ATHEROSCLEROSIS PREVENTION STUDY (LAPS)$84,633
M01 · FY2005 · RR
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)$29,158
M01 · FY2005 · RR
LUPUS ATHEROSCLEROSIS PREVENTION STUDY (LAPS) SUPPLEMENT$15,701
M01 · FY2005 · RR
PROGRAM PROJECT IN THE GENETICS OF SLE$3,489
M01 · FY2005 · RR
Lupus Cohort$622,360
R01 · FY2004 · AR
Brain Connections$438,720
R01 · FY2004 · AR
Prospective Lupus Cohort Study of Disease Activity and Predictors of Morbidity$402,215
M01 · FY2004 · RR
Revision of ACR Classification Criteria for SLE$245,250
R01 · FY2004 · AR
Lupus Atherosclerosis Prevention Study (LAPS)$23,827
M01 · FY2004 · RR
Lupus Atherosclerosis Prevention Study (LAPS) Supplement$19,116
M01 · FY2004 · RR
Program Project in the Genetics of SLE$157
M01 · FY2004 · RR
Lupus Cohort$661,385
R01 · FY2003 · AR
Brain Connections$448,035
R01 · FY2003 · AR
Lupus Cohort$762,537
R01 · FY2002 · AR
Brain Connections$578,130
R01 · FY2002 · AR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
PHASE II TRIAL OF IDEC 131 IN PATIENTS WITH ACTIVE SLE$0
M01 · FY2002 · RR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SLE$0
M01 · FY2002 · RR
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS$0
M01 · FY2002 · RR
DETECTION OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
SPECIALIZED CENTER OF RESEARCH--SYSTEMIC LUPUS ERYTHRMATOSUS$0
M01 · FY2002 · RR
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY/PREDICTORS/MORBIDITY/HEALTH$0
M01 · FY2002 · RR
MULTICENTER TRIAL OF REPEATED DOSE OF LJP 394 IN PATIENTS WITH SLE$0
M01 · FY2002 · RR
GL701 IN FEMALES WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
AUTOANTIBODY DIVERSIFICATION IN SLE FLARES$216,966
P50 · FY2001 · AR
HOPKINS LUPUS COHORT$150,000
R01 · FY2001 · AR
PHASE II TRIAL OF IDEC 131 IN PATIENTS WITH ACTIVE SLE$0
M01 · FY2001 · RR
MULTICENTER TRIAL OF REPEATED DOSE OF LJP 394 IN PATIENTS WITH SLE$0
M01 · FY2001 · RR
GL701 IN FEMALES WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SLE$0
M01 · FY2001 · RR
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS$0
M01 · FY2001 · RR
DETECTION OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
SPECIALIZED CENTER OF RESEARCH--SYSTEMIC LUPUS ERYTHRMATOSUS$0
M01 · FY2001 · RR
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY/PREDICTORS/MORBIDITY/HEALTH$0
M01 · FY2001 · RR
HOPKINS LUPUS COHORT$267,764
R01 · FY2000 · AR
AUTOANTIBODY DIVERSIFICATION IN SLE FLARES$190,151
P50 · FY2000 · AR
RAND. CLINICAL TRIAL OF HIGH DOSE IMMUNOBLATIVE THERA$183,570
N01 · FY2000 · AR
PHASE II TRIAL OF IDEC 131 IN PATIENTS WITH ACTIVE SLE$0
M01 · FY2000 · RR
AUTOANTIBODY DIVERSIFICATION IN SLE FLARES$0
P50 · FY2000 · AR
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS$0
M01 · FY2000 · RR
DETECTION OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
SPECIALIZED CENTER OF RESEARCH--SYSTEMIC LUPUS ERYTHRMATOSUS$0
M01 · FY2000 · RR
PROSPECTIVE LUPUS COHORT STUDY OF DISEASE ACTIVITY/PREDICTORS/MORBIDITY/HEALTH$0
M01 · FY2000 · RR
MULTICENTER TRIAL OF REPEATED DOSE OF LJP 394 IN PATIENTS WITH SLE$0
M01 · FY2000 · RR
GL701 IN FEMALES WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SLE$0
M01 · FY2000 · RR